FDA Expands Tukysa Approval for HER2-Positive Metastatic Breast Cancer Maintenance

The FDA has approved Pfizer's Tukysa, in combination with trastuzumab and pertuzumab, as a first-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. This approval, based on Phase 3 trial data, offers a chemotherapy-free option to delay disease progression, moving the oral therapy into an earlier treatment setting for patients.